Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples